

106TH CONGRESS
2D SESSION

S. 2607

To promote pain management and palliative care without permitting assisted suicide and euthanasia, and for other purposes.

IN THE SENATE OF THE UNITED STATES

MAY 23, 2000

Mr. WYDEN introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To promote pain management and palliative care without permitting assisted suicide and euthanasia, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Pain Relief Promotion
5 Act of 2000”.

6 **SEC. 2. FINDINGS.**

7 Congress finds that—

8 (1) in the first decade of the new millennium
9 there should be a new emphasis on pain manage-
10 ment and palliative care;

1 (2) the use of certain narcotics and other drugs
2 or substances with a potential for abuse is strictly
3 regulated under the Controlled Substances Act;

4 (3) the dispensing and distribution of certain
5 controlled substances by properly registered practi-
6 tioners for legitimate medical purposes are permitted
7 under the Controlled Substances Act and imple-
8 menting regulations;

9 (4) the dispensing or distribution of certain
10 controlled substances for the purpose of relieving
11 pain and discomfort even if it increases the risk of
12 death is a legitimate medical purpose and is permis-
13 sible under the Controlled Substances Act;

14 (5) inadequate treatment of pain, especially for
15 chronic diseases and conditions, irreversible diseases
16 such as cancer, and end-of-life care, is a serious pub-
17 lic health problem affecting hundreds of thousands
18 of patients every year; physicians should not hesitate
19 to dispense or distribute controlled substances when
20 medically indicated for these conditions; and

21 (6) for the reasons set forth in section 101 of
22 the Controlled Substances Act (21 U.S.C. 801), the
23 dispensing and distribution of controlled substances
24 for any purpose affect interstate commerce.

1 **TITLE I—PROMOTING PAIN MAN-**
2 **AGEMENT AND PALLIATIVE**
3 **CARE**

4 **SEC. 101. ACTIVITIES OF AGENCY FOR HEALTHCARE RE-**
5 **SEARCH AND QUALITY.**

6 Part A of title IX of the Public Health Service Act
7 (42 U.S.C. 299 et seq.) is amended by adding at the end
8 the following:

9 **“SEC. 903. PROGRAM FOR PAIN MANAGEMENT AND PALLIA-**
10 **TIVE CARE RESEARCH AND QUALITY.**

11 “(a) IN GENERAL.—Subject to subsections (e) and
12 (f) of section 902, the Director shall carry out a program
13 to accomplish the following:

14 “(1) Promote and advance scientific under-
15 standing of pain management and palliative care.

16 “(2) Collect and disseminate protocols and evi-
17 dence-based practices regarding pain management
18 and palliative care, with priority given to pain man-
19 agement for terminally ill patients, and make such
20 information available to public and private health
21 care programs and providers, health professions
22 schools, and hospices, and to the general public.

23 “(b) DEFINITION.—In this section, the term ‘pain
24 management and palliative care’ means—

1 “(1) the active, total care of patients whose dis-
 2 ease or medical condition is not responsive to cura-
 3 tive treatment or whose prognosis is limited due to
 4 progressive, far-advanced disease; and

5 “(2) the evaluation, diagnosis, treatment, and
 6 management of primary and secondary pain, wheth-
 7 er acute, chronic, persistent, intractable, or associ-
 8 ated with the end of life;

9 the purpose of which is to diagnose and alleviate pain and
 10 other distressing signs and symptoms and to enhance the
 11 quality of life, not to hasten or postpone death.”.

12 **SEC. 102. ACTIVITIES OF HEALTH RESOURCES AND SERV-**
 13 **ICES ADMINISTRATION.**

14 (a) IN GENERAL.—Part D of title VII of the Public
 15 Health Service Act (42 U.S.C. 294 et seq.) is amended—

16 (1) by redesignating sections 754 through 757
 17 as sections 755 through 758, respectively; and

18 (2) by inserting after section 753 the following:

19 **“SEC. 754. PROGRAM FOR EDUCATION AND TRAINING IN**
 20 **PAIN MANAGEMENT AND PALLIATIVE CARE.**

21 “(a) IN GENERAL.—The Secretary, in consultation
 22 with the Director of the Agency for Healthcare Research
 23 and Quality, may award grants, cooperative agreements,
 24 and contracts to health professions schools, hospices, and
 25 other public and private entities for the development and

1 implementation of programs to provide education and
2 training to health care professionals in pain management
3 and palliative care.

4 “(b) PRIORITY.—In making awards under subsection
5 (a), the Secretary shall give priority to awards for the im-
6 plementation of programs under such subsection.

7 “(c) CERTAIN TOPICS.—An award may be made
8 under subsection (a) only if the applicant for the award
9 agrees that the program to be carried out with the award
10 will include information and education on—

11 “(1) means for diagnosing and alleviating pain
12 and other distressing signs and symptoms of pa-
13 tients, especially terminally ill patients, including the
14 medically appropriate use of controlled substances;

15 “(2) applicable laws on controlled substances,
16 including laws permitting health care professionals
17 to dispense or administer controlled substances as
18 needed to relieve pain even in cases where such ef-
19 forts may unintentionally increase the risk of death;
20 and

21 “(3) recent findings, developments, and im-
22 provements in the provision of pain management
23 and palliative care.

24 “(d) PROGRAM SITES.—Education and training
25 under subsection (a) may be provided at or through health

1 professions schools, residency training programs and other
2 graduate programs in the health professions, entities that
3 provide continuing medical education, hospices, and such
4 other programs or sites as the Secretary determines to be
5 appropriate.

6 “(e) EVALUATION OF PROGRAMS.—The Secretary
7 shall (directly or through grants or contracts) provide for
8 the evaluation of programs implemented under subsection
9 (a) in order to determine the effect of such programs on
10 knowledge and practice regarding pain management and
11 palliative care.

12 “(f) PEER REVIEW GROUPS.—In carrying out section
13 799(f) with respect to this section, the Secretary shall en-
14 sure that the membership of each peer review group in-
15 volved includes individuals with expertise and experience
16 in pain management and palliative care for the population
17 of patients whose needs are to be served by the program.

18 “(g) DEFINITION.—In this section, the term ‘pain
19 management and palliative care’ means—

20 “(1) the active, total care of patients whose dis-
21 ease or medical condition is not responsive to cura-
22 tive treatment or whose prognosis is limited due to
23 progressive, far-advanced disease; and

24 “(2) the evaluation, diagnosis, treatment, and
25 management of primary and secondary pain, wheth-

1 er acute, chronic, persistent, intractable, or associ-
2 ated with the end of life;
3 the purpose of which is to diagnose and alleviate pain and
4 other distressing signs and symptoms and to enhance the
5 quality of life, not to hasten or postpone death.”.

6 (b) AUTHORIZATION OF APPROPRIATIONS; ALLOCA-
7 TION.—

8 (1) IN GENERAL.—Section 758 of the Public
9 Health Service Act (as redesignated by subsection
10 (a)(1) of this section) is amended, in subsection
11 (b)(1)(C), by striking “sections 753, 754, and 755”
12 and inserting “sections 753, 754, 755, and 756”.

13 (2) AMOUNT.—With respect to section 758 of
14 the Public Health Service Act (as redesignated by
15 subsection (a)(1) of this section), the dollar amount
16 specified in subsection (b)(1)(C) of such section is
17 deemed to be increased by \$5,000,000.

18 **SEC. 103. DECADE OF PAIN CONTROL AND RESEARCH.**

19 The calendar decade beginning January 1, 2001, is
20 designated as the “Decade of Pain Control and Research”.

21 **SEC. 104. EFFECTIVE DATE.**

22 The amendments made by this title shall take effect
23 on the date of enactment of this Act.

1 **TITLE II—USE OF CONTROLLED**
2 **SUBSTANCES CONSISTENT**
3 **WITH THE CONTROLLED SUB-**
4 **STANCES ACT**

5 **SEC. 201. REINFORCING EXISTING STANDARD FOR LEGITI-**
6 **MATE USE OF CONTROLLED SUBSTANCES.**

7 (a) IN GENERAL.—Section 303 of the Controlled
8 Substances Act (21 U.S.C. 823) is amended by adding at
9 the end the following:

10 “(i)(1) For purposes of this Act and any regulations
11 to implement this Act, alleviating pain or discomfort in
12 the usual course of professional practice is a legitimate
13 medical purpose for the dispensing, distributing, or admin-
14 istering of a controlled substance that is consistent with
15 public health and safety, even if the use of such a sub-
16 stance may increase the risk of death. Nothing in this sec-
17 tion authorizes intentionally dispensing, distributing, or
18 administering a controlled substance for the purpose of
19 causing death or assisting another person in causing
20 death.

21 “(2)(A) Notwithstanding any other provision of this
22 Act, in determining whether a registration is consistent
23 with the public interest under this Act, the Attorney Gen-
24 eral shall give no force and effect to State law authorizing
25 or permitting assisted suicide or euthanasia.

1 “(B) Paragraph (2) applies only to conduct occurring
2 after the date of enactment of this subsection.

3 “(3) Nothing in this subsection shall be construed to
4 alter the roles of the Federal and State governments in
5 regulating the practice of medicine. Regardless of whether
6 the Attorney General determines pursuant to this section
7 that the registration of a practitioner is inconsistent with
8 the public interest, it remains solely within the discretion
9 of State authorities to determine whether action should
10 be taken with respect to the State professional license of
11 the practitioner or State prescribing privileges.

12 “(4) Nothing in the Pain Relief Promotion Act of
13 2000 (including the amendments made by such Act) shall
14 be construed—

15 “(A) to modify the Federal requirements that a
16 controlled substance be dispensed only for a legiti-
17 mate medical purpose pursuant to paragraph (1); or

18 “(B) to provide the Attorney General with the
19 authority to issue national standards for pain man-
20 agement and palliative care clinical practice, re-
21 search, or quality;

22 except that the Attorney General may take such other ac-
23 tions as may be necessary to enforce this Act.”.

24 (b) PAIN RELIEF.—Section 304(c) of the Controlled
25 Substances Act (21 U.S.C. 824(c)) is amended—

1 (1) by striking “(c) Before” and inserting the
2 following:

3 “(c) PROCEDURES.—

4 “(1) ORDER TO SHOW CAUSE.—Before”; and

5 (2) by adding at the end the following:

6 “(2) BURDEN OF PROOF.—At any proceeding
7 under paragraph (1), where the order to show cause
8 is based on the alleged intentions of the applicant or
9 registrant to cause or assist in causing death, and
10 the practitioner claims a defense under paragraph
11 (1) of section 303(i), the Attorney General shall
12 have the burden of proving, by clear and convincing
13 evidence, that the practitioner’s intent was to dis-
14 pense, distribute, or administer a controlled sub-
15 stance for the purpose of causing death or assisting
16 another person in causing death. In meeting such
17 burden, it shall not be sufficient to prove that the
18 applicant or registrant knew that the use of con-
19 trolled substance may increase the risk of death.”.

20 **SEC. 202. EDUCATION AND TRAINING PROGRAMS.**

21 Section 502(a) of the Controlled Substances Act (21
22 U.S.C. 872(a)) is amended—

23 (1) by striking “and” at the end of paragraph
24 (5);

1 (2) by striking the period at the end of para-
2 graph (6) and inserting “; and”; and

3 (3) by adding at the end the following:

4 “(7) educational and training programs for
5 Federal, State, and local personnel, incorporating
6 recommendations, subject to the provisions of sub-
7 sections (e) and (f) of section 902 of the Public
8 Health Service Act, by the Secretary of Health and
9 Human Services, on the means by which investiga-
10 tion and enforcement actions by law enforcement
11 personnel may better accommodate the necessary
12 and legitimate use of controlled substances in pain
13 management and palliative care.

14 Nothing in this subsection shall be construed to alter the
15 roles of the Federal and State governments in regulating
16 the practice of medicine.”.

17 **SEC. 203. FUNDING AUTHORITY.**

18 Notwithstanding any other provision of law, the oper-
19 ation of the diversion control fee account program of the
20 Drug Enforcement Administration shall be construed to
21 include carrying out section 303(i) of the Controlled Sub-
22 stances Act (21 U.S.C. 823(i)), as added by this Act, and
23 subsections (a)(4) and (c)(2) of section 304 of the Con-
24 trolled Substances Act (21 U.S.C. 824), as amended by
25 this Act.

1 **SEC. 204. EFFECTIVE DATE.**

2 The amendments made by this title shall take effect
3 on the date of enactment of this Act.

○